Partnerships

Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue them in partnership. Active Biotech has a global license agreement with NeoTX for the development and commercialization of naptumomab in cancer indications, since 2016. Active Biotech also has a global patent license agreement with Oncode Institute, acting on behalf of Erasmus MC, for tasquinimod in myelofibrosis. Several academic partnerships are currently in place with selected institutions, including Abramson Cancer Center, Philadelphia, US for tasquinimod in multiple myeloma, MD Anderson Cancer Center, Texas, Stitching-Haemato-Oncologie Volwassenen Netherlands (HOVON) for tasquinimod in myelofibrosis, as well as Stanford Medicine and the Global Ophthalmic Research Center (GORC), for laquinimod in inflammatory eye diseases.

NeoTX Therapeutics Ltd.

On October 26, 2016 – Active Biotech announced an agreement with NeoTX Therapeutics Ltd., for the development and commercialization of naptumomab estafenatox for cancer immunotherapy.

The licensing agreement grants NeoTX exclusive rights to develop and commercialize naptumomab estafenatox worldwide in cancer indications. The total deal value amounts to USD 71 million and is contingent upon achievement of clinical, regulatory and commercial milestones. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.